A phase I clinical trial of CAR-T directed against mesothelin was conducted (NCT02159716), and the preliminary results revealed that an infusion of CAR-mesothelin T cells was well tolerated without an off-tumor effect or cytokine release syndrome (CRS) in patients with mesothelioma, OC, and pancreatic cancer. The gene discussed is MSLN; the disease is familial pancreatic carcinoma.